Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UFT-based chemoradiation with or without cetuximab after neoadjuvant GEM-CAP for locally advanced pancreatic cancer
ISRCTN65518365Phase 2Terminated
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Mar 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of tegafur + uracil, cetuximab, gemcitabine, capecitabine and folinic acid in pancreatic cancer (PC) (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: One-year overall survival rate. Started Mar 2009; status: terminated.
02
Drugs
tegafur + uracilcetuximabgemcitabinecapecitabinefolinic acid
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ISRCTN65518365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN65518365.